These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 28583311)

  • 21. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
    Ajili F; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guérin Failure in Patients with Non-muscle-invasive Bladder Cancer.
    Strandgaard T; Lindskrog SV; Nordentoft I; Christensen E; Birkenkamp-Demtröder K; Andreasen TG; Lamy P; Kjær A; Ranti D; Wang YA; Bieber C; Prip F; Rasmussen J; Steiniche T; Birkbak N; Sfakianos J; Horowitz A; Jensen JB; Dyrskjøt L
    Eur Urol; 2022 Dec; 82(6):646-656. PubMed ID: 36210217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis.
    Packiam VT; Labbate CV; Boorjian SA; Tarrell R; Cheville JC; Avulova S; Sharma V; Tsivian M; Adamic B; Mahmoud M; Werntz RP; Smith ND; Karnes RJ; Tollefson MK; Steinberg GD; Frank I
    Urol Oncol; 2021 Jul; 39(7):436.e1-436.e8. PubMed ID: 33485764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mixed low- and high-grade non-muscle-invasive bladder cancer: a histological subtype with favorable outcome.
    Schubert T; Danzig MR; Kotamarti S; Ghandour RA; Lascano D; Dubow BP; Decastro GJ; Benson MC; McKiernan JM
    World J Urol; 2015 Jun; 33(6):847-52. PubMed ID: 25149472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
    McElree IM; Steinberg RL; Martin AC; Richards J; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA; Packiam VT
    J Urol; 2022 Sep; 208(3):589-599. PubMed ID: 35892270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guérin therapy for bladder cancer.
    Chiong E; Kesavan A; Mahendran R; Chan YH; Sng JH; Lim YK; Kamaraj R; Tan TM; Esuvaranathan K
    Eur Urol; 2011 Mar; 59(3):430-7. PubMed ID: 21163569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette-Guérin and Immune Checkpoint Inhibitors.
    Baek SW; Leem SH
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer.
    Kobayashi M; Fujiyama N; Tanegashima T; Narita S; Yamamoto Y; Fujimoto N; Ueda S; Takeuchi A; Numakura K; Habuchi T; Matsuyama H; Eto M; Shiota M
    Cancer Immunol Immunother; 2022 Mar; 71(3):727-736. PubMed ID: 34379177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
    Sfakianos JP; Kim PH; Hakimi AA; Herr HW
    J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
    Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
    BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with Non-Muscle-Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guérin Intravesical Instillation Therapy.
    Maeyama R; Ikeda M; Shimura S; Amano N; Murakami Y; Yamada Y; Koguchi D; Tachibana T; Kawamura M; Sakata Y; Hagiwara M; Matsumoto K; Iwamura M
    Chemotherapy; 2023; 68(4):190-196. PubMed ID: 35390791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphism in autophagy gene ATG2B is not associated with bladder cancer recurrence after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy in Asian patients.
    Zang Z; Lim YK; Chan YH; Raman L; Esuvaranathan K; Chiong E; Mahendran R
    Urol Oncol; 2021 Apr; 39(4):238.e1-238.e7. PubMed ID: 33250346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.
    Kamat AM; Li R; O'Donnell MA; Black PC; Roupret M; Catto JW; Comperat E; Ingersoll MA; Witjes WP; McConkey DJ; Witjes JA
    Eur Urol; 2018 May; 73(5):738-748. PubMed ID: 29055653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.